← Eichor
Study identifier: NCT04792034 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution

Condition: ENT Disorder · Nasal Procedures · Nasal Anesthesia  ·  Sponsor: Noden Pharma

PhasePhase 3
Planned participants40
Who can joinAll sexes, 12 Years to 18 Years
Healthy volunteersNo

About this study

The purpose of this study is to assess the pharmacokinetic (PK) properties, safety and tolerability following a single dose administration of GOPRELTO® or NUMBRINO™ as an anesthetic for diagnostic procedures and surgeries on or through the mucous membranes of the nasal cavities in pediatric adolescent subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Robert Puchlaski, M.D  ·  803-256-7076; 803-549-2467  ·  rpuchalski@me.com

Always discuss trial participation with your own doctor first.

Locations (4)

SCENT Sleep and Allergy, 110 Highland Center DriveColumbia, South Carolina, United StatesRecruiting
SCENT Sleep and Allergy, 145 Park CentralColumbia, South Carolina, United StatesRecruiting
South Carolina ENT, Sleep and AllergyColumbia, South Carolina, United StatesRecruiting
SCENT Sleep and Allergy, 15 Exchange Dr.Lugoff, South Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04792034